Author: Wesley J. Horton
Biotech companies operate in an environment where innovation, investment, and regulation intersect. Every clinical trial milestone, regulatory interaction, financing event, and investor communication creates opportunities for growth. At the same time, those same events can create litigation risk when outcomes do not align with expectations.
Securities litigation involving biotech and life sciences companies has remained elevated in recent years, driven by increased scrutiny of clinical trial disclosures, regulatory communications, and investor-facing statements. While every case is different, many claims follow a familiar pattern: expectations rise, results disappoint, and plaintiffs look backward to determine whether investors were adequately informed.
The most effective litigation strategies often begin long before a lawsuit is filed. Companies that prioritize disciplined communication, strong governance, and proactive legal involvement are often better positioned to navigate setbacks when they arise.
Why Are Biotech Companies Frequent Targets of Securities Litigation?
Biotech companies face a higher risk of litigation because their business models depend heavily on future clinical, regulatory, and commercial outcomes that are inherently uncertain.
Investors are often evaluating products that are still in development, regulatory approvals that have not yet been granted, and technologies that may take years to reach commercialization. As a result, public disclosures frequently involve projections and expectations about future events.
When actual results differ from investor expectations, stock price declines can trigger shareholder claims alleging that prior disclosures were misleading or incomplete.
This risk is not limited to public companies. Private biotech companies regularly communicate with investors, lenders, strategic partners, and potential acquirers. Those communications can become the subject of disputes if expectations are not met or stakeholders believe material information was omitted.
Which Disclosures Create the Greatest Litigation Risk?
Clinical trial disclosures remain one of the most common sources of biotech securities litigation.
Statements regarding efficacy, safety, enrollment progress, regulatory pathways, and anticipated outcomes frequently become the focus of shareholder claims. However, litigation risk is expanding beyond traditional clinical disclosures.
Today, investors and regulators are paying increasing attention to issues involving artificial intelligence, patient data usage, cybersecurity, privacy practices, and technology-driven research tools. As biotech companies incorporate these technologies into their businesses, disclosures surrounding them are receiving greater scrutiny.
The takeaway is simple: every public statement should be evaluated through the lens of potential future litigation.
How Can Companies Communicate Optimism Without Increasing Litigation Exposure?
Biotech executives face a difficult balancing act. Investors expect leadership teams to communicate confidence in their products and scientific progress. At the same time, overly enthusiastic messaging can create legal exposure.
The most effective approach is disciplined communication grounded in real-time data.
Investors deserve transparency. The key is ensuring that public statements accurately reflect the information available at the time they are made and that risks are communicated alongside opportunities.
Strong disclosures do not avoid discussing positive developments. Instead, they present a balanced picture that acknowledges both potential upside and potential uncertainty.
Consistency is equally important. Everyone communicating with investors should be operating from the same set of facts, whether they are executives, investor relations professionals, or business development personnel.
What Do Plaintiffs’ Attorneys Look for After a Stock Price Decline?
After a significant stock drop, plaintiffs’ attorneys often review years of public communications looking for statements that can be portrayed as inconsistent with later developments.
Earnings calls, investor presentations, analyst meetings, conference appearances, media interviews, and regulatory disclosures frequently become the focus of investigations.
Even isolated comments can become central allegations in a securities complaint.
For example, in litigation involving eHealth, Inc., plaintiffs alleged that statements made during earnings calls suggested certain commission receivables carried no additional costs, while the company allegedly incurred related customer care and retention expenses. While this complaint was ultimately dismissed, it illustrates how routine, and unscripted, executive communications can become a focal point of securities litigation when investors later claim they were misled.
This is why message discipline matters. Every public communication should be viewed as a potential exhibit in future litigation.
Well-crafted disclosures, appropriate cautionary language, and properly drafted forward-looking statements can significantly strengthen a company’s position if litigation arises.
Why Are Internal Investigations Important?
When shareholder claims or regulatory inquiries emerge, one of the first priorities should be understanding the facts.
Internal investigations help companies assess potential exposure, preserve evidence, understand what information existed at specific points in time, and determine how that information was communicated internally and externally.
The process often begins with document preservation. Companies should immediately suspend routine deletion policies and ensure that relevant emails, messages, and records are retained.
Organizations should also identify and interview key stakeholders, including members of clinical development teams, finance personnel, executives, investor relations professionals, and board members.
In many cases, contemporaneous documents ultimately support the company’s position by demonstrating that management acted reasonably and in good faith based on the information available at the time.
Why Should Litigators Be Involved Before a Dispute Arises?
Many organizations involve litigators only after a lawsuit has been filed. In the biotech industry, that approach can be costly.
One of the most effective ways to reduce litigation risk is to involve litigators before a dispute arises. Securities litigators evaluate disclosures, investor communications, governance practices, and transaction documents through the lens of how those materials may be scrutinized in future litigation.
At FBFK Law, litigators frequently collaborate with corporate, securities, and transactional attorneys before major announcements, financing events, strategic transactions, and regulatory developments. This cross-disciplinary approach helps companies identify potential vulnerabilities early and address them before they become claims.
How Can Biotech Companies Reduce Litigation Risk During M&A Transactions?
Biotech remains one of the most active sectors for mergers, acquisitions, and strategic transactions.
These deals often involve complex valuation questions tied to intellectual property, clinical data, regulatory milestones, and future performance expectations. In many biotech transactions, a significant portion of the value is tied to future milestones, making clear drafting and careful risk allocation particularly important.
As a result, disputes can arise over deal pricing, earn-outs, milestone payments, contingent value rights, and post-closing obligations.
Bringing litigators into the transaction process can help identify areas that may create ambiguity or future disputes. When litigators and deal attorneys collaborate early, transaction documents are often stronger, clearer, and more likely to withstand future challenges.
What Should Companies and Boards Do Before a Major Announcement?
Whether announcing clinical trial results, regulatory developments, financing events, or strategic transactions, leadership teams should approach the process with discipline and coordination.
Before making a significant announcement, companies and boards should consider several key questions:
- Is the underlying data complete, current, and adequately validated?
- Have the clinical, finance, communications, and legal teams reviewed the proposed messaging?
- Are material risks being disclosed alongside potential opportunities?
- Have insider trading considerations and blackout periods been addressed?
- Are investor-facing communications consistent across all channels?
- Does the announcement include appropriate forward-looking statement protections?
Taking the time to address these questions before information reaches the market can help reduce risk while supporting informed decision-making.
What Is the Most Common Mistake Biotech Companies Make?
One of the most common mistakes is allowing executives or employees to speak off the cuff about significant developments.
Investor conferences, earnings call question-and-answer sessions, media interviews, and informal discussions can create unintended liability when comments go beyond the underlying data or create expectations that later prove inaccurate.
While formal presentations often receive extensive review, unscripted remarks frequently receive less attention despite carrying similar legal risk.
Companies should ensure that message discipline extends beyond prepared statements and into every interaction with investors, analysts, and the market.
Key Takeaways for Biotech Executives
While no company can eliminate litigation risk entirely, there are several practical steps leadership teams can take immediately:
- Ensure investor communications are supported by current data.
- Establish clear disclosure controls and approval processes.
- Create consistent messaging across investor-facing teams.
- Involve advisors before major announcements.
- Preserve documents immediately when litigation is anticipated.
- Conduct regular reviews of governance and compliance procedures.
- Foster collaboration among legal, finance, clinical, and executive teams.
Innovation will always involve uncertainty. The goal is not to eliminate risk but to create the governance structures, disclosure controls, and communication strategies that allow companies to innovate confidently while protecting enterprise value.
Litigation risk management should not be viewed as a defensive exercise. When approached strategically, it can help companies communicate more effectively, make better decisions, and build credibility with investors and stakeholders.
Organizations that take a proactive approach to litigation risk are often better positioned to navigate setbacks, maintain investor confidence, protect enterprise value, and continue pursuing innovation with confidence.
